Influenza (Flu) 

Influenza seasonal epidemic disease affects 15-60 million people in the United States each year, causing an estimated 44,000 deaths and 186,000 hospitalizations annually. Pandemic influenza has occurred three times over the last century. The 1918 outbreak alone killed more than 40 million people worldwide. Avian influenza (bird flu) is a lethal influenza strain that has created worldwide concern because its infection can be transferred among humans. The mortality rate among humans exceeds 50%.

Immuron is developing an all natural formulation of anti-influenza antibodies and other protective proteins to provide immediate acting immunity to an individual at risk of exposure to influenza virus infection. A series of animal studies already shown the effectiveness of the Immuron innovative approach,  "Flubody", and clinical trials are being planned. The product is designed to be marketed as an over the counter natural remedy with strong clinical data to support its claims.

The new natural product would provide immediate acting protection for at-risk individuals, complementing but not competing with existing influenza vaccines. Immuron brings a rapid manufacturing capability to address circulating influenza viruses not present in a current vaccine that may have significant public health value as well.

Development and testing is being carried out by Immuron and expert influenza researchers at The University of Melbourne.